Here is a complete, stepwise drug selection guide for an unknown cause, mild-to-moderate generalized body rash with itching:
Drug Selection for Generalized Skin Rash (Whole Body)
The treatment follows a stepwise approach based on severity and duration.
Step 1 - First-Line: Antihistamines (Always Start Here)
Antihistamines block H1 receptors, reducing histamine-mediated itching, redness, and hive formation - the main drivers of most generalized rashes.
Second-Generation H1 Antihistamines (Preferred - Non-Sedating)
These are given first because they are effective, safe, and do not cause significant drowsiness:
| Drug | Dose (Adult) | Frequency |
|---|
| Cetirizine (Zyrtec) | 10 mg | Once daily |
| Loratadine (Claritin) | 10 mg | Once daily |
| Fexofenadine (Allegra) | 180 mg | Once daily |
| Levocetirizine | 5 mg | Once daily |
| Desloratadine | 5 mg | Once daily |
| Bilastine | 20 mg | Once daily |
These are the backbone of treatment for urticaria and generalized allergic rash.
First-Generation H1 Antihistamines (Sedating - Use at Night)
Used when rash is preventing sleep, or added at night to a daytime second-generation antihistamine:
| Drug | Dose | Notes |
|---|
| Chlorphenamine | 4 mg three times daily | Can give up to 12 mg at night |
| Hydroxyzine | 10-25 mg three times daily | Good for severe itch |
| Diphenhydramine | 10-25 mg at night | Highly sedating |
| Doxepin | 10-50 mg at night | Very potent H1 + H2 blocker; useful in chronic urticaria |
A common clinical strategy: second-generation antihistamine in the morning + first-generation (e.g., hydroxyzine) at night for better itch control.
Step 2 - Add H2 Antihistamine if Inadequate Response
H2 receptors are also present in the skin. Adding an H2 blocker gives maximal antihistamine blockade:
- Famotidine 20 mg twice daily (preferred)
- Cimetidine 400 mg twice daily
This combination (H1 + H2 blocker) is evidence-based for urticaria that does not respond to H1 alone.
Step 3 - Corticosteroids (For Moderate-Severe or Refractory Rash)
When the rash is widespread, persistent, or not responding to antihistamines:
-
Prednisolone / Prednisone: 0.5 mg/kg/day orally
- Used for short courses only (3-5 days) as "rescue treatment" for severe exacerbations
- Not recommended for long-term use due to side effects
-
Betamethasone or Dexamethasone injection can be given as a single dose for acute severe allergic rash
Steroids reduce inflammation quickly but do not address the underlying cause.
Step 4 - Topical Treatment (Alongside Systemic Drugs)
For symptomatic relief of itching and redness:
- Topical corticosteroids (e.g., hydrocortisone 1% cream, betamethasone cream): applied to affected areas
- Calamine lotion: soothing, anti-itch
- Emollients/moisturizers: if rash is associated with dry skin or eczema
Step 5 - Second-Line for Chronic Rash (Lasting >6 Weeks)
If the rash is chronic and not responding:
| Drug | Dose | Indication |
|---|
| Montelukast (leukotriene antagonist) | 10 mg once daily | Aspirin-sensitive urticaria |
| Dapsone | 50-100 mg daily | If biopsy shows neutrophilic infiltrate |
| Omalizumab (anti-IgE biologic) | 300 mg SC monthly | Chronic spontaneous urticaria unresponsive to antihistamines |
Important: When to Give Epinephrine (Adrenaline)
If the rash is associated with:
- Throat swelling / angioedema
- Difficulty breathing
- Drop in blood pressure (anaphylaxis)
→ Epinephrine 0.3-0.5 mg IM (thigh) immediately - this is a medical emergency.
Quick Summary: Drug Selection Hierarchy
Mild-Moderate Whole Body Rash
↓
1st Line: 2nd-generation antihistamine (Cetirizine / Loratadine / Fexofenadine)
↓ (not responding)
Add H2 blocker (Famotidine) + nighttime 1st-gen antihistamine (Hydroxyzine)
↓ (still not responding or moderate-severe)
Short course Prednisolone 0.5 mg/kg/day (3-5 days only)
↓ (chronic, >6 weeks)
Montelukast or Omalizumab
Key takeaway: The first drug to choose for a generalized rash with itching is a non-sedating second-generation antihistamine like cetirizine or loratadine - safe, effective, once daily, and well-tolerated. Add steroids only if the rash is severe or not responding.
Sources: Dermatology 2-Volume Set 5th Edition; Morgan & Mikhail's Clinical Anesthesiology